Percheron Therapeutics (AU:PER) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Percheron Therapeutics has announced a change in the interest of its director, James Garner, who acquired 3 million unquoted options, exercisable at 8.3 cents per option by July 2029. This acquisition, approved at the recent Annual General Meeting, could influence investor sentiment and the company’s market activity.
For further insights into AU:PER stock, check out TipRanks’ Stock Analysis page.